Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Inmarsat Accepts GBP3.4 Billion Takeover Offer

Mon, 25th Mar 2019 07:45

LONDON (Alliance News) - Stock prices in London are seen opening in the red on Monday, tracking Asian equity markets lower following heavy losses in the US on Friday, amid fears of an impending US recession.In early UK company news, Inmarsat has agreed to a USD3.4 billion takeover offer from Apax Partners, Majestic Wine announced a restructuring plan, ConvaTec appointed a new chief executive, and Provident Financial and Non-Standard Finance traded barbs. IG futures indicate the FTSE 100 index is to open 33.69 points lower at 7,173.90. The blue chip index closed down 147.72 points, or 2.0%, at 7,207.59 on Friday.The Japanese Nikkei 225 index ended down 3.0%. In China, the Shanghai Composite closed down 1.4%, while the Hang Seng index in Hong Kong is down 2.0%.In the US on Friday, Wall Street ended lower, with the Dow Jones Industrial Average down 1.8%, S&P 500 down 1.9% Nasdaq Composite down 2.5%.US equities tumbled on Friday after the spread between three-month Treasury bills and 10-year note yields inverted for the first time since 2007. Historically, an inverted yield curve - where long-term rates fall below short-term - has signalled an imminent recession.FTSE 250 satellite firm Inmarsat said it has accepted a USD3.4 billion takeover offer from Apax Partners. An Apax-led consortium will pay USD7.21 per share in cash, including Inmarsat's final dividend. The price matched the one indicated in a disclosure last week.Wine retailer Majestic Wine announced a 'Group Transformation Plan' to revitalise the business by placing increased focus on its Naked Wines acquisition, whose name it will take on. Majestic Wine expects to achieve GBP500 million sales target for its 2019 financial year, with adjusted pretax profit for the year expected to be around the current consensus level. Moreover, it will accelerate new customer investment in Naked by an additional GBP6 million per annum to GBP26 million in financial 2020, up from the current level of GBP20 million.The company said it expects to recognise largely non-cash restructuring charges of up to GBP10 million in financial 2019.Majestic Wine said it is to rename itself as Naked Wines to focus on a single brand and business model."It is clear that Naked Wines has the potential for strong sustainable growth, and we will deliver the best results for our shareholders, customers, people and suppliers by focusing all our energies on delivering that potential. We also believe that a transformed Majestic business does have the potential to be a long-term winner, but that we risk not maximising the potential of Naked if we try to do both. Where we have no choice but to close stores we will aim to minimise job losses by migration into Naked," CEO Rowan Gormley said. Water utility Pennon Group will take a GBP16 million hit due to financial problems at partner Interserve, Pennon said Monday.Pennon, whose financial year ends on Sunday, had booked a provision of GBP8 million related to its exposure to Interserve, but this has now been increased. Interserve is now in administration, and Pennon "is seeking further clarification" on Interserve's situation, meaning the provision could increase."We will continue to pursue recovery of all amounts due from the operating subsidiary Interserve Construction Ltd and will take all the necessary legal and procedural steps to achieve this," said Pennon.On the trading front, South West Water continues to perform strongly, Pennon said, with its return on retained earnings expected around 12%, an outperformance. Wound dressings maker ConvaTec Group said it has appointed Genus Chief Executive Karim Bitar as its new CEO starting September 30. Genus said it has commenced the search for a replacement. In addition, ConvaTec Chair Christopher Gent is to retire at the annual general meeting in May. Interim CEO Rick Anderson has agreed to temporarily serve as executive chair until a new chair has been appointed, the company added.Subprime lender Provident Financial reiterated its stance that the offer from Non-Standard Finance is not in the best interests of its shareholders. Non-Standard Finance hit back saying Provident Financial's formal response "changes nothing". Non-Standard Finance urged Provident shareholders to accept the offer "without delay". Sports Direct International confirmed it had made an offer to troubled department store chain Debenhams for its Magasin du Nord business in Denmark, which "addresses Debenhams' liquidity concerns". The sportswear retailer said it did not receive any response from Debenhams. Sports Direct added that Debenhams was not open to alternative third party proposals."Regarding the guidance provided to Sports Direct on behalf of the Debenhams board, if guidance as to what might represent a workable solution for Debenhams could result in no equity value for Debenhams' current shareholders, from Sports Direct's perspective and that of Debenhams' wider stakeholders, that is not a workable solution," Sports Direct said. Anglo-Swedish drugmaker AstraZeneca said the European Commission has approved its Forxiga medication for adults with type-1 diabetes. The company said Forxiga is currently under regulatory review in Japan and the US, with a decision expected in the first and second half of 2019, respectively.Elisabeth Bjork, head of the late cardiovascular, renal & metabolism, R&D BioPharmaceuticals unit, said: "Forxiga is the first oral medicine approved in Europe as an adjunct to insulin for people living with type-1 diabetes whose glucose levels are not adequately controlled with insulin alone. We look forward to bringing Forxiga to a patient population that has not had any approved oral medicines available before."The pound was quoted at USD1.3175 early Monday, down from USD1.3207 at the London equities close Friday, amid Brexit-related uncertainty.UK Prime Minister Theresa May is battling to stay in power as members of Parliament seek to seize control of legislative business in a bid to secure a softer Brexit.At the start of another crunch week in Westminster, the Commons is due to vote on an amendment which would force a series of indicative votes on alternatives to the prime minister's withdrawal agreement. The proposal seeks to pave the way for a series of indicative votes in the Commons on Wednesday, effectively taking control of the Brexit process out of the hands of the government.After a weekend which saw two senior ministers dismiss reports of a "coup" to oust the PM, May will convene her Cabinet in the morning before she updates the Commons on the Brexit process following last week's European Council summit where she agreed to delay Britain's departure beyond March 29.Meanwhile, US Treasury Secretary Steven Mnuchin and US Trade Representative Robert Lighthizer will travel to Beijing for trade talks set to begin on Thursday, the White House said Saturday.Chinese Vice Premier Liu He will visit Washington on April 3, the White House also announced.The new round of talks on Thursday, the fourth since December, comes as both sides have said substantial progress is being made despite negotiators missing the original March 1 deadline to complete the talks.A light economic events calendar on Monday has German IFO Business sentiment at 0900 GMT.

More News
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
1 Dec 2023 08:52

LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI

(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.

Read more
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.